# Critical Limb Ischemia Rapid Delivery by SurgWerks-CLI Kit and VXP System

Study · id `cardio:ct-nct02538978` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02538978](<https://clinicaltrials.gov/study/NCT02538978>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02538978

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 224 participants.

## Technical summary

Registry record NCT02538978. Randomized; quadruple masking; primary purpose treatment. Start 2017-01 (registry gives no type); primary completion 2018-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 224 participants (planned count; ClinicalTrials.gov record NCT02538978, source copy `cardio:ctgov-nct02538978-2016-07-28`, retrieved 2026-10-31)
- Start date: 2017-01 (registry gives no type) (ClinicalTrials.gov record NCT02538978, source copy `cardio:ctgov-nct02538978-2016-07-28`, retrieved 2026-10-31)
- Primary completion: 2018-12 (anticipated) (ClinicalTrials.gov record NCT02538978, source copy `cardio:ctgov-nct02538978-2016-07-28`, retrieved 2026-10-31)
- Completion: 2019-03 (anticipated) (ClinicalTrials.gov record NCT02538978, source copy `cardio:ctgov-nct02538978-2016-07-28`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02538978-2016-07-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: Critical Limb Ischemia Rapid Delivery by SurgWerks-CLI Kit and VXP System
- Acronym: CLIRST III
- Condition: Critical Limb Ischemia (CLI)
- Intervention (Biological): Autologous Bone Marrow Concentrate (aBMC)
- Intervention (Biological): Placebo Control (diluted autologous peripheral blood)
- Lead sponsor: Cesca Therapeutics, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)

## Provenance

Content hash: c6152b05f3bcff0213cfc5a89abeecf9bc4da9d0c321ec47067189a6c84f4889
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
